1. Home
  2. MGYR vs AGEN Comparison

MGYR vs AGEN Comparison

Compare MGYR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magyar Bancorp Inc.

MGYR

Magyar Bancorp Inc.

N/A

Current Price

$18.35

Market Cap

115.2M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.30

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGYR
AGEN
Founded
1922
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.2M
126.2M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
MGYR
AGEN
Price
$18.35
$3.30
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
4.8K
410.2K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
2.25%
N/A
EPS Growth
26.83
N/A
EPS
0.50
0.37
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$5.19
Revenue Next Year
N/A
$68.25
P/E Ratio
$35.55
$9.12
Revenue Growth
N/A
89.95
52 Week Low
$13.52
$1.38
52 Week High
$20.00
$7.34

Technical Indicators

Market Signals
Indicator
MGYR
AGEN
Relative Strength Index (RSI) 43.93 53.66
Support Level $17.07 $2.90
Resistance Level $17.87 $4.72
Average True Range (ATR) 0.33 0.18
MACD -0.08 0.06
Stochastic Oscillator 0.80 85.48

Price Performance

Historical Comparison
MGYR
AGEN

About MGYR Magyar Bancorp Inc.

Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: